Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Effekten av ett smarttelefonassisterat hybridhjärtrehabiliteringsprogram hos patienter med hjärtsvikt. (SHCR-HF)

15 november 2026 uppdaterad av: National Taiwan University Hospital

The aim of this randomized controlled trial is to compare the impact of a case manager-led smartphone-assisted hybrid cardiac rehabilitation program with usual care in patients with HF. Participants will undergo a 12-week program led by a case manager and assisted by a smartphone. The study aims to answer two main questions:

  1. Is the novel cardiac rehabilitation model feasible for patients with HF?
  2. Does the intervention group show a significant improvement in exercise capacity and adherence compared to the usual care group?

Studieöversikt

Status

Rekrytering

Betingelser

Studietyp

Interventionell

Inskrivning (Beräknad)

150

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Hung-Jui Chuang, MD
  • Telefonnummer: 67034 00886-2-23123456
  • E-post: rexintwo@gmail.com

Studieorter

      • Taipei, Taiwan
        • Rekrytering
        • Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 80 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Patients with heart failure between the ages of 18 and 80 years old.
  • NYHA (New York Heart Association) functional classification of 1 to 3.
  • Patients must be in a stable condition and under outpatient follow-up.

Exclusion Criteria:

  • Patients who have contraindications for exercise according to the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription.
  • Patients who are unable to complete cardiopulmonary exercise testing.
  • Patients who are unable to follow verbal instructions.
  • Patients who are unable to walk independently or pedal a stationary bicycle.
  • Patients who are unable to use communication app on a smartphone.
  • Patients who already engage in physical activity exceeding the recommended moderate intensity of 150 minutes per week or are currently participating in cardiac rehabilitation.
  • Patients who do not provide consent to participate in the trial.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: smartphone-assisted hybrid cardiac rehabilitation (SHCR)

Participants receive a 12-wk case manager-led smartphone-assisted hybrid cardiac rehabilitation with follow-up at 12 week and 6 months.

The 12-week case manager-led SHCR program includes:

  • Customized exercise prescriptions following ACSM's heart failure guidelines.
  • A hybrid program combining in-person sessions, home self-exercise, and videoconferencing for exercise coaching(optional), supported by a smartphone app.
  • Case managers instruct patients on a communication app for weekly follow-ups, health education messages, exercise reminders, and progress tracking, including metrics like blood pressure, heart rate, weight, and symptoms.
Inget ingripande: Usual care

Participants receive usual care including general education and exercise suggestion.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change of peak oxygen uptake
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.

Peak oxygen uptake will be assessed using cardiopulmonary exercise test before intervention, at 12 weeks (post-intervention), and at 6 months.

at baseline, 12 weeks(post-intervention), and 6 months.
Change of 6 minute walking test
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.

6 minute walking test will be performed before intervention, at 12 weeks (post-intervention), and at 6 months.

at baseline, 12 weeks(post-intervention), and 6 months.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Adherence to prescribed exercise
Tidsram: 12 weeks(post-intervention)

We will evaluate the percentage of completed prescribed exercises at 12 weeks.

12 weeks(post-intervention)
Evaluation of Quality of life
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.

The investigators will assess the change in 36-Item Short Form Survey(SF-36).

at baseline, 12 weeks(post-intervention), and 6 months.
Depression
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.

The investigators will assess the change in Patient Health Questionnaire (PHQ-9). The PHQ-9 score ranges from 0-27. Higher scores indicate worsen symptoms.

at baseline, 12 weeks(post-intervention), and 6 months.
Anxiety
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.

The investigators will assess the change in Generalized Anxiety Disorder scale (GAD-7). The GAD-7 score ranges 0-21. Higher scores indicate worsen symptoms.

at baseline, 12 weeks(post-intervention), and 6 months.
Evaluation of physical activity
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.

The investigators will assess the change in physical activity using International Physical Activity Questionnaire(IPAQ) Taiwan version.

at baseline, 12 weeks(post-intervention), and 6 months.
Evaluation of grip strength
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.

The grip strength will be measured using a grip goniometer with the participants seated and the elbow flexed at 90 degrees.

at baseline, 12 weeks(post-intervention), and 6 months.
Evaluation of frailty
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.

The investigators will evaluate the change in the Clinical Frailty Scale, which ranges from 1 to 9. Higher scores represent greater illness.

at baseline, 12 weeks(post-intervention), and 6 months.
Blood test: Total cholesterol
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.

The Total cholesterol will be tested in the laboratory.

at baseline, 12 weeks(post-intervention), and 6 months.
Blood test: LDL
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.

The LDL will be tested in the laboratory.

at baseline, 12 weeks(post-intervention), and 6 months.
Blood test: HDL
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.

The HDL will be tested in the laboratory.

at baseline, 12 weeks(post-intervention), and 6 months.
Blood test: Triglyceride
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.

The Triglyceride will be tested in the laboratory.

at baseline, 12 weeks(post-intervention), and 6 months.
Blood test: NT-proBNP
Tidsram: at baseline, 12 weeks(post-intervention), and 6 months.

The NT-proBNP will be tested in the laboratory.

at baseline, 12 weeks(post-intervention), and 6 months.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Hung-Jui Chuang, MD, Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

26 januari 2024

Primärt slutförande (Beräknad)

1 december 2028

Avslutad studie (Beräknad)

1 december 2028

Studieregistreringsdatum

Först inskickad

1 maj 2023

Först inskickad som uppfyllde QC-kriterierna

15 maj 2023

Första postat (Faktisk)

24 maj 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

15 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • 202302009RINC

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera